Tucatinib Continues to Show Benefit in Pretreated HER2+ Breast Cancer With Brain Metastases
The primary analysis of the phase 3 HER2CLIMB-02 demonstrates that tucatinib slowed disease progression in patients with HER2-positive metastatic breast cancer, including those with brain metastases.
FDA Is Investigating Potential Secondary Cancer Risks Associated CAR T-Cell Therapy
There have been reports of T-cell malignancies among patients who have undergone CD19- or BCMA-directed autologous CAR T-cell immunotherapies.
Sotorasib Plus Panitumumab Shows Potential in Refractory KRAS G12C+ mCRC
Sotorasib plus panitumumab showed consistent efficacy across key subgroups of patients with metastatic colorectal cancer.
First-Line Immunotherapy Is Associated With Worse Survival Outcomes in Synchronous mRCC
Patients with synchronous metastatic renal cell carcinoma experienced worse outcomes with first line immune-checkpoint inhibitors-based combinations vs those with metachronous disease.
Avelumab Safety Profile Remains Consistent in Long-Term JAVELIN Bladder 100 Post Hoc Analysis
Patients with advanced urothelial carcinoma who received avelumab reported any-grade treatment-related adverse events at a rate of 78.2%.
Ribociclib Plus Fulvestrant Leads to Longer PFS in Metastatic Breast Cancer
Patients with metastatic breast cancer who received ribociclib plus fulvestrant achieved a median progression-free survival of 18.1 months vs 5.29 months with placebo/fulvestrant.
Durvalumab Plus Guadecitabine Shows Early Activity in Checkpoint Inhibitor–Naïve ccRCC
The overall response rate with durvalumab and guadecitabine was 23% in patients with advanced ccRCC who had received 1 or fewer therapies.
Ruxolitinib Reduces Hematocrit Levels in 6-Month Analysis of Patients With Polycythemia Vera
After 6 months of treatment with ruxolitinib, patients with polycythemia vera experienced a significant reduction in hematocrit levels compared with baseline.
Savolitinib Plus Durvalumab Induces High Response Rates in MET-Driven Papillary Renal Cancer
A combination of immune checkpoint inhibitor and MET-targeted therapy led to high responses in patients with MET-driven papillary renal cancer, although the regimen missed its primary end point.
Adding Docetaxel to Radiation Boosts Survival in Cisplatin-Ineligible HNSCC
Findings from a phase 2/3 trial found better disease-free and overall survival outcomes with radiation plus docetaxel vs radiation alone in head and neck squamous cell carcinoma.
Ibrutinib Plus Prednisone Does Not Improve Response Rates in cGVHD
First-line ibrutinib plus prednisone missed the primary endpoint in the phase 3 iNTEGRATE trial by not improving the response rate in patients with chronic graft-versus-host-disease compared with placebo plus prednisone.
Hepatic Arterial Infusion Chemotherapy-Administered FOLFOX Delivers Longer DFS Rates in Hepatocellular Carcinoma
Adjuvant treatment with hepatic arterial infusion chemotherapy-infused FOLFOX improved disease-free survival rates for patients with hepatocellular carcinoma with microvascular invasion.
Real-World Data Showcases Ibrutinib Efficacy in Relapsed/Refractory Mantle Cell Lymphoma
Ibrutinib demonstrated encouraging responses for patients with relapsed/refractory mantle cell lymphoma in a real-world setting.
Chemoimmunotherapy Yields Promising Objective Responses in Patients With High-Risk Neuroblastoma
Among 71 patients with neuroblastoma, 48.6% achieved an objective response and 29% achieved a complete response with a 4-drug combination.
Adding Cediranib to Olaparib Increases Treatment Efficacy, But Raises Toxicity Concerns, in mCRPC
A regimen of cediranib and olaparib improved radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer compared with olaparib monotherapy. However, the rate of dose reductions was doubled with the combination.
Ipilimumab Plus Niraparib Combo Extends PFS Rates in Pancreatic Cancer
A combination of niraparib plus ipilimumab were associated with a 6-month PFS rate of 59.6%, whereas a combination of nivolumab plus the PARP inhibitor yielded a rate of 20.6%.
Galunisertib Boosts Efficacy of Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer
When combined with neoadjuvant chemotherapy, galunisertib induced complete response rates surpassing rates achieved with standard-of-care therapy in locally advanced rectal cancer.
Kahl Discusses the Future of Maintenance Therapy in Mantel Cell Lymphoma
An expert with the Washington University School of Medicine in St Louis outlines the benefit of rituximab, and other maintenance therapies, for patients with mantel cell lymphoma who are in remission.
Better Research Funding Practices Are Needed to Mitigate Disparities in Cancer Incidence and Mortality
The way in which cancer research is funded is an understudied area of health disparities, says Suneel Kamath, MD.
Ghosh Discusses Liso-cel Approval in Second-line LBCL
Nilanjan Ghosh, MD, PhD, discusses the expanded access second-line lisocabtagene maraleucel affords patients with large B-cell lymphoma.
Updated PFS Data Continue to Support Nivolumab Plus Relatlimab in Advanced Melanoma
Relatlimab, a human LAG-3 blocking antibody, plus nivolumab, elicited superior progression-free survival in patients with advanced melanoma compared to nivolumab alone.
Cabozantinib/Nivolumab Showcases Clinical Benefit in Papillary Non–Clear Cell RCC
Phase 2 trial findings indicate that cabozantinib plus nivolumab may be effective in treating patients with non-clear cell renal cell carcinoma with papillary histology.
Endocrine Therapy Plus Ovarian Suppression Remains An Effective Treatment Strategy in HR+, HER2-, Early Breast Cancer
Investigators Present Real-World Experiences With T-DXd Following HER2 Status Changes
Maintenance Pembrolizumab/Olaparib Falls Short in Locally Advanced, Metastatic TNBC
Neoadjuvant Pembrolizumab Improves pCR Across ER+ Breast Cancer Subgroups
2 Clarke Drive Cranbury, NJ 08512